CDMP gives primary care an efficient means to support the roughly 30+% of diabetes patients whose disease is uncontrolled and who are currently left to manage this complex disease on their own.
All
Team
Company
Patients
Physicians
Hospital
Partners
Mission
Innovation Details
Investor Info
Due Diligence Docs
Supporters
Comments
Updates
About our project
The problem we solve: Diabetes care is broken for many Americans. An estimated 10-12 million people living with diabetes have uncontrolled disease and are left to manage this complex condition on their own. Existing solutions in the market are too expensive, don’t fit clinical workflows or don’t address both the clinical and behavioral aspects critical to managing chronic disease. An opportunity exists to use data, combined with human expertise to deliver truly comprehensive care in way that serves patients and fits how primary care is delivered today.
About our solution:
The CDMP solution includes both cloud-based and mobile tools for data collection in between visits, and a single-screen patient dashboard, accessible directly from within their EHR. The primary care team works collaboratively with the patient to gather data on educational and nutritional care plans, home monitor information, surveys, and other activities. This patient data is then processed with clinical data from the EHR and presented together with key behavioral information to provide a comprehensive view of the patient. CDMP is available as an integrated technology platform or a full turnkey service for primary care.
Progress to
date:
CDMP is in the market and installed at multiple sites.
About Our Team
Creator: Philip Heifetz
Location: Pennsylvania
Education: Wharton MBA (Health Care)
Bio: Executive with 25+ years experience in health care (digital health and life sciences). In industry, have had success in sales, financing, licensing and business development. Led or participated in raising over $60 million venture capital and completed business development deals that brought in nearly $10 million cash proceeds. Roles have included CEO, CFO and head of business development.
He has a strong personal network and history of volunteer activities within health care. He co-founded and co-heads a 1350-member non-profit organization (Philadelphia Health IT Circle) dedicated to healthcare innovation. Mr. Heifetz was also on the board of HIMSS North America and previously served on the board of the Wharton Health Care Alumni Association.
Title: CEO
Advanced Degree(s): BSc, MBA
About Team Members
Boz Coburn
Head Marketing, BS, MBA Biography: Boz is building on a long career in health care and pharmaceuticals to develop Saturn Care’s sales and market presence. He has spent 30 years in various finance, venture capital, business development and corporate development roles in health care. A CPA by training, the majority of his experience has been with the Sanofi organization. This included management positions in both the U.S. and France. Most recently, Boz served as CFO for Locemia Solutions, a developer of a novel hypoglycemia rescue device that exited via a sale to Eli Lilly.
Title: Head Marketing Advanced Degree(s): BS, MBA LinkedIn:https://www.linkedin.com/in/bozcoburn/
RJ Kedziora
CTO and Co-Founder, BSc, MS, MBA Biography: A highly-experienced software architect who has led development projects in health care on behalf of some of the largest corporations and non-profit organizations in the world. For 15 years he has served as Co-Founder and Chief Technology Officer of Estenda Solutions, where he has overseen projects addressing a wide spectrum of health care needs. He previously managed health IT projects for First Consulting Group, which later became part of CSC. He is the architect of Saturn Care’s CDMP project and has been integral to its development and commercialization since inception.
Title: CTO and Co-Founder Advanced Degree(s): BSc, MS, MBA LinkedIn:https://www.linkedin.com/in/rjkedziora/
Jim Doucette
Advisor, BS, MBA Biography: Jim comes to Saturn Care as a thought leader in the areas of digital health care innovation and patient engagement, particularly as these apply to the pharmaceuticals industry. He was most recently part of a team at Merck that was developing and deploying digital medication adherence and patient engagement solutions in partnership with several large health systems. In other roles at Merck, Jim has served as part of senior management within Merck-owned divisions, and has been part of special cross-functional teams developing plans and strategies with the goal of leveraging technology to advance Merck brands.
Title: Advisor Advanced Degree(s): BS, MBA LinkedIn:https://www.linkedin.com/in/james-doucette-0496a110/
John Brooks III
Advisor, BS, MS Biography: John L. Brooks III is the managing director of Healthcare Capital, LLC. Healthcare Capital. Mr. Brooks is the former President and CEO of the Joslin Diabetes Center. He has co-founded seven life sciences companies, including Insulet (PODD), a disruptive insulin delivery company. He was a co-founder of Prism Venture Partners, a $1.25B VC firm. Previously, Mr. Brooks was the Emerging Business Group General Manager at Pfizer/Valleylab, where he was responsible for Pfizer’s Hospital Products Group’s minimally invasive surgery and new medical technologies businesses. As President/General Manager at Pfizer/Strato, he led the growth of a rapidly evolving vascular access medical device business.
Title: Advisor Advanced Degree(s): BS, MS LinkedIn:https://www.linkedin.com/in/john-brooks-ab04432/
William Polonsky, PhD, CDE
Advisor, BA,MS,M.Phil,PhD Biography: Dr. Bill Polonsky is Associate Clinical Professor in Psychiatry at the University of California San Diego. An active researcher in the field of behavioral diabetes, he has served on the editorial boards of Diabetes Care, Diabetes Forecast, Clinical Diabetes, Diabetes Self-Management and Diabetes Health. He received his PhD in clinical psychology from Yale University and has served as Senior Psychologist at the Joslin Diabetes Center in Boston, faculty member at Harvard Medical School and Chairman of the National Certification Board for Diabetes Educators.
Title: Advisor Advanced Degree(s): BA,MS,M.Phil,PhD LinkedIn:https://www.linkedin.com/in/william-polonsky-phd-cde-161b204/
Stanley Schwartz, M.D., FACP, FACE
Advisor, BA, MD Biography: Stanley Schwartz, MD, is an endocrinologist who specializes in the diagnosis and treatment of the cardio-metabolic syndrome, impaired glucose tolerance, diabetes, hypoglycemia disorders, and general endocrinologic problems. For over 32 years, Dr. Schwartz was an Associate Professor at the University of Pennsylvania, most recently directing the Diabetes Program at the Philadelphia Heart Institute, becoming Emeritus Associate Professor in 2011. Dr. Schwartz received his MD from the University of Chicago, completed his residency at the University of Pennsylvania and an Endocrine Fellowship at the University of Chicago.
Title: Advisor Advanced Degree(s): BA, MD LinkedIn:https://www.linkedin.com/in/stan-schwartz-65238613/
Joseph Humphry, M.D.
Advisor, BS, MD Biography: Joseph Humphry, MD, is Program Medical Director for the Lanai Community Health Center. He is a primary internist with special interest in diabetes who has spent the majority of his clinical career working with minority and underprivileged patients including Native Hawaiians and Pacific Islanders. He is a graduate of the University of California at San Francisco School of Medicine and completed his internship at San Joaquin Medical Center in Stockton California and completed internal medicine residency at the University of Rochester and UCLA.
Dr. Humphry was recently announced as a winner of the 2017 Davies Award from HIMSS.
Title: Advisor Advanced Degree(s): BS, MD LinkedIn:https://www.linkedin.com/in/joseph-humphry-1245117/
Martin Lafontaine
Advisor, BSc Biography: Martin possesses more than 20 years of marketing experience in the pharmaceutical and medical device industry, having spent a major part of his professional career working for the British multinational GlaxoSmithkline, with a strong focus in the area of diabetes. Martin is also the former Chief Commercial Officer of Montreal-based pharmaceutical development company Locemia Solutions, which was sold to Eli Lilly in 2015. Diagnosed with type 1 diabetes at age 13, Martin is a model for people living with diabetes and serves on the Board of Directors of the non-profit Behavioral Diabetes Institute as well as other organizations.
Title: Advisor Advanced Degree(s): BSc LinkedIn:https://www.linkedin.com/in/martin-lafontaine-6ba0186/
About Our Company
Saturn Care
Location: 1 West Elm Street Ste 150 Conshohocken, PA 19072
- to have your primary care provider know not just your numbers, but about you as a person?
- to have office visits be more personal, and be able to talk about more than just your clinical results?
- to not feel so rushed with your doctor?
- to have contact with your doctor's office whenever you want, and to know that all of your questions can be answered in a timely and accurate manner?
CDMP offers these benefits -- visit www.saturncare.com to learn more.
How We Help Physicians
Physicians:
-> get instant access to a full picture of your patient, including their behavioral profile and risk scores, all in a single screen and from within the electronic health record
-> saves time and informs, so you can have more meaningful communication with patients
-> have the time and information (eg, remote monitor data) to make better clinical decisions
-> collaborate with the care team to utilize Medicare Chronic Care Management (CCM) revenue codes as part of an overall diabetes population health strategy
Diabetes Nurse Educators:
-> be more efficient, and be enabled to be more comprehensive with more diabetes patients
-> bill for currently uncompensated support time (through CCM)
How We Help Hospitals
- Improve quality and outcomes for diabetes and co-morbid conditions
- Avoid costly complications due to diabetes
- Make primary care more efficient and integrated with the Education team
How We Help Partners
Contact us to learn how CDMP can help partners better integrate with primary care and benefit from improved outcomes under value-based care.
Challenge Mission
Market Size
We estimate that there are at least 10 million Americans living with diabetes who have uncontrolled blood sugar and limited contact with the health system. (NCQA and NHANES data)
Our total U.S. market opportunity is calculated as 10 million x annual price per patient, and is over $750 million. The total global market includes nearly 400 million diabetes patients worldwide.
Projected 3 Year Growth
We project strong growth - please contact us for more information.
How We Will Make Money
We charge on a monthly per patient basis. We sell both the technology platform and as a turnkey, tech-enabled service.
About our Competition
Diabetes is a crowded space. Unlike the digital health apps, disease management programs and population health solutions in the market, CDMP offers:
- a comprehensive solution that addresses both the clinical and behavioral aspects of care
- a clinically-integrated solution that is part of the primary care workflow through integration with the electronic health record
- an evidence-based solution supported by published, peer-reviewed data in well-respected journals
Progress with Customers to date
Saturn Care has paying customers, and we are proud members of the Startup Health Transformer community.
New Orleans and Our Company
Diabetes is one of the greatest health challenges to Louisiana and New Orleans, and Saturn Care welcomes the opportunity to be part of the solution. We have contacts at the state level (Secretary of Department of Health) and at Tulane University, and we would be both thrilled and honored to be able to participate in building a great healthcare innovation community in this awesome city!
Innovation Details
Intellectual Property Summary
We have secured full rights to CDMP through licensing and acquistion.
Clinical Information
CDMP is the result of over 12 years and $50 million of grant-based research prior to the formation of Saturn Care. During that period, two key published randomized controlled studies were completed in partnership with a consortium including Joslin Diabetes Center in Boston, MA and Baystate Health in Springfield, MA.
The purpose of the first study was to evaluate the clinical usefulness of a nurse-led diabetes care program (Comprehensive Diabetes Management Program, CDMP) for poorly controlled Hispanic type 2 diabetes (T2DM) patients in an urban community health center setting.
The study enrolled 21 patients in the intervention arm plus 18 patients into an attention control arm, and was conducted in an urban Latino community health center. Among the findings of the 12-month study were:
the intervention group experienced a 1.6% drop in HbA1c, which is greater than what is seen with many drug therapies
Nearly 2x higher proportion of patients met clinical goals for A1c, blood pressure, eye exams and foot exams
Greater improvements in Diabetes Distress and treatment satisfaction were seen
The overall conclusion was, ”The CDMP intervention was more effective than an attention control condition in helping patients meet evidence-based guidelines for diabetes care.”
Results were published in the Diabetes Educator, which is the scientific journal of the American Association of Diabetes Educators. (https://www.ncbi.nlm.nih.gov/pubmed/21918206)
A larger follow-on study was completed under a RO1 grant from the National Institutes of Health. That study had a similar protocol, but enrolled 399 poorly controlled patients and included 5 visits over 6 months. Again, the population included a low income, poorly controlled, Latino population. In this case, the control arm (“usual care”) received a Robert Wood Johnson Foundation funded diabetes self management education program.
Highlights from the study included:
Twice as many intervention patients reached an A1c goal of <7.0 vs. the control arm
The intervention group saw nearly a 0.8% drop in A1c relative to the control arm
Significantly lower diabetes distress at follow-up for the intervention group vs control
In conclusion, “The diabetes dashboard (ie, CDMP) intervention significantly improved diabetes-related outcomes among Latinos with poorly controlled T2D compared with a similar diabetes team condition without access to the diabetes dashboard.”
The study was published in the April 2015 edition of Diabetes Care, which is the clinical journal of the American Diabetes Assocation.
At this time, we do not require FDA clearance to market the current version of CDMP. We have an alpha version of a clinical decision support tool in development, and we are awaiting the upcoming FDA guidance on CDS before determining a strategy for release.
How we will use the funds raised
All funding received from MedStartr will be dedicated to software development.
Thank You
We appreciate all the help and support for this most important mission!
Investor Info
Market Size
We estimate that there are at least 10 million Americans living with diabetes who have uncontrolled blood sugar and limited contact with the health system. (NCQA and NHANES data)
Our total U.S. market opportunity is calculated as 10 million x annual price per patient, and is over $750 million. The total global market includes nearly 400 million diabetes patients worldwide.
Projected 3 Year Growth
Available upon request
Revenue Model
Monthly subscription model, details available by request.
Competitors
Diabetes is a crowded space. Unlike the digital health apps, disease management programs and population health solutions in the market, CDMP offers:
- a comprehensive solution that addresses both the clinical and behavioral aspects of care
- a clinically-integrated solution that is part of the primary care workflow through integration with the electronic health record
- an evidence-based solution supported by published, peer-reviewed data in well-respected journals
Traction
Saturn Care has paying customers, and we are proud members of the Startup Health Transformer community.
Due Diligence Docs
Please note that access to the company's confidential materials is limited. Click this button to request access from the Company and its representatives.
Pottstown, PA-based PMSI has selected the CDMP platform for use in their Chronic Care Management (CCM) program. The CCM program is a comprehensive support service of the patient education team under the leadership of Debbie Zlomek, RN, CDE, and is open to all Part B Medicare patients living with diabetes and one or more other chronic conditions.
131
Medstartr Index Score
126
Interest Score
1
Adoption Score
23
Likes
0
Partners
0
Pilots
1
Investors
This campaign has ended but you can still get involved.
See options below.
$ 100,020pledged of $ 20,000 goal
$ 100,000Investor, Pilot & Parnter interest to date.
Help us find best new ideas to fund by telling us what you think. Your feedback goes
straight to the team behind this project in private, so tell them what you really think.
Executive with 25+ years experience in health care (digital health and life sciences). In industry, have had success in sales, financing, licensing and bus...
CDMP gives primary care an efficient means to support the roughly 30+% of diabetes patients whose disease is uncontrolled and who are currently left to manage this complex disease on their own.
Thank you for visiting!
This area is for community members only. Please signin or signup and join our global community of people who care about medical innovation.
